This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanhoutte, P. M. Search for Related Content PubMed PubMed Citation Articles by Vanhoutte, P. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE NITRIC OXIDE

(Circulation Research. 2008;102:866.)
© 2008 American Heart Association, Inc.

Editorials

Arginine and Arginase

Endothelial NO Synthase Double Crossed?

Paul M. Vanhoutte

From the Department of Pharmacology, Li Ka Shing Faculty of Medicine, The University of Hong Kong.

Correspondence to Paul M. Vanhoutte, Head, Department of Pharmacology, Li Ka Shing Faculty of Medicine, University of Hong Kong, 2/F Laboratory Block, 21 Sassoon Rd, Hong Kong. E-mail vanhoutt@hkucc.hku.hk

See related article, pages 923–932

Key Words: arginine • arginases • NO • NO synthase • oxidized LDL

An extract of the first 250 words of the full text is provided, because this article has no abstract.

In a remarkable article published in this issue of Circulation Research, Ryoo et al¹ propose endothelial arginase II as a novel target for the treatment of atherosclerosis. Actually, they already had done so 2 years ago, based on work mainly on cultured human aortic endothelial cells,² which indeed appeared to provide an unexpected way to explain endothelial dysfunction in terms of NO production.³ This new road to endothelial dysfunction proposed that oxidized low-density lipoproteins (LDLs), which we all agree are a main culprit in the initiation of the atherosclerotic process, increase the activity of arginase II, which, in turn, decreases NO production presumably by shunting the common substrate arginine away from endothelial NO synthase (eNOS) (Figure).

View larger version (27K):   Figure. Model of endothelial dysfunction in the hypercholesterolemic mouse as proposed by Ryoo and colleagues.1,2 Left, In the normal mouse aortic endothelium, L-arginine (L-Arg) is transformed by eNOS to NO, which exerts its well-documented beneficial effects (most are not shown for the sake of clarity), including inhibition of the oxidation of LDLs to OxLDL. The byproduct of the reaction, L-citrulline (L-Cit), inhibits arginase II (AaII), which is constrained to the microtubules (MT). Right, In the aortic endothelium of the ApoE–/– and the wild-type hypercholesterolemic mice, the accumulation of OxLDL dislocates arginase II from the microtubules and augments its activity. Arginase II competes with endothelial NO synthase for the common substrate L-arginine, leading to uncoupling of NO synthase and the production of superoxide anions (O,2]), which further enhance . . . [Full Text of this Article]

This article has been cited by other articles:

				C. Jung, A. T. Gonon, P.-O. Sjoquist, J. O. Lundberg, and J. Pernow Arginase inhibition mediates cardioprotection during ischaemia-reperfusion Cardiovasc Res, September 18, 2009; (2009) cvp303v2. [Abstract] [Full Text] [PDF]